Loading clinical trials...
Loading clinical trials...
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study
Conditions
Interventions
Irinotecan
Raltitrexed
Locations
1
China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Start Date
December 1, 2016
Primary Completion Date
December 1, 2019
Completion Date
December 1, 2020
Last Updated
February 14, 2017
NCT06696768
NCT04704661
NCT05489211
NCT04657068
NCT06625775
NCT06607458
Lead Sponsor
China Medical University, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions